CURIS INC (CRIS) Fundamental Analysis & Valuation

NASDAQ:CRIS • US2312693094

Current stock price

0.6717 USD
-0.01 (-1.87%)
Last:

This CRIS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CRIS Profitability Analysis

1.1 Basic Checks

  • In the past year CRIS has reported negative net income.
  • CRIS had a negative operating cash flow in the past year.
  • CRIS had negative earnings in each of the past 5 years.
  • In the past 5 years CRIS always reported negative operating cash flow.
CRIS Yearly Net Income VS EBIT VS OCF VS FCFCRIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • CRIS has a Return On Assets of -37.97%. This is comparable to the rest of the industry: CRIS outperforms 57.17% of its industry peers.
  • The Return On Equity of CRIS (-138.81%) is worse than 61.82% of its industry peers.
Industry RankSector Rank
ROA -37.97%
ROE -138.81%
ROIC N/A
ROA(3y)-68.16%
ROA(5y)-56.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRIS Yearly ROA, ROE, ROICCRIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400 600

1.3 Margins

  • Looking at the Gross Margin, with a value of 99.52%, CRIS belongs to the top of the industry, outperforming 99.03% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CRIS has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for CRIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y0.93%
CRIS Yearly Profit, Operating, Gross MarginsCRIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CRIS Health Analysis

2.1 Basic Checks

  • CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRIS has been increased compared to 1 year ago.
  • CRIS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CRIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRIS Yearly Shares OutstandingCRIS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
CRIS Yearly Total Debt VS Total AssetsCRIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • CRIS has an Altman-Z score of -91.73. This is a bad value and indicates that CRIS is not financially healthy and even has some risk of bankruptcy.
  • CRIS has a Altman-Z score of -91.73. This is amonst the worse of the industry: CRIS underperforms 94.19% of its industry peers.
  • CRIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -91.73
ROIC/WACCN/A
WACC9.81%
CRIS Yearly LT Debt VS Equity VS FCFCRIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • CRIS has a Current Ratio of 0.49. This is a bad value and indicates that CRIS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.49, CRIS is not doing good in the industry: 92.05% of the companies in the same industry are doing better.
  • CRIS has a Quick Ratio of 0.49. This is a bad value and indicates that CRIS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.49, CRIS is not doing good in the industry: 91.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.49
CRIS Yearly Current Assets VS Current LiabilitesCRIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CRIS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.46% over the past year.
  • Looking at the last year, CRIS shows a very negative growth in Revenue. The Revenue has decreased by -13.43% in the last year.
  • CRIS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.72% yearly.
EPS 1Y (TTM)58.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-13.43%
Revenue growth 3Y-2.41%
Revenue growth 5Y-2.72%
Sales Q2Q%-65.98%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.75% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 63.19% on average over the next years. This is a very strong growth
EPS Next Y27.46%
EPS Next 2Y32.36%
EPS Next 3Y26.32%
EPS Next 5Y14.75%
Revenue Next Year3.67%
Revenue Next 2Y31.87%
Revenue Next 3Y64.75%
Revenue Next 5Y63.19%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRIS Yearly Revenue VS EstimatesCRIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M
CRIS Yearly EPS VS EstimatesCRIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

1

4. CRIS Valuation Analysis

4.1 Price/Earnings Ratio

  • CRIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CRIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRIS Price Earnings VS Forward Price EarningsCRIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRIS Per share dataCRIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CRIS's earnings are expected to grow with 26.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.36%
EPS Next 3Y26.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRIS Dividend Analysis

5.1 Amount

  • CRIS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRIS Fundamentals: All Metrics, Ratios and Statistics

CURIS INC

NASDAQ:CRIS (4/16/2026, 11:45:17 AM)

0.6717

-0.01 (-1.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)05-04
Inst Owners19.95%
Inst Owner Change0%
Ins Owners3.26%
Ins Owner Change1.26%
Market Cap26.85M
Revenue(TTM)9.44M
Net Income(TTM)-7.58M
Analysts82
Price Target14.28 (2025.95%)
Short Float %0.16%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.98%
Min EPS beat(2)-8.93%
Max EPS beat(2)16.89%
EPS beat(4)2
Avg EPS beat(4)7.46%
Min EPS beat(4)-8.93%
Max EPS beat(4)25.09%
EPS beat(8)4
Avg EPS beat(8)-2.04%
EPS beat(12)7
Avg EPS beat(12)-1.09%
EPS beat(16)9
Avg EPS beat(16)0.19%
Revenue beat(2)1
Avg Revenue beat(2)-28.07%
Min Revenue beat(2)-65.02%
Max Revenue beat(2)8.88%
Revenue beat(4)2
Avg Revenue beat(4)-16.04%
Min Revenue beat(4)-65.02%
Max Revenue beat(4)8.88%
Revenue beat(8)5
Avg Revenue beat(8)3.59%
Revenue beat(12)6
Avg Revenue beat(12)0.29%
Revenue beat(16)6
Avg Revenue beat(16)-2.69%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.27%
EPS NQ rev (3m)-1.27%
EPS NY rev (1m)-15.76%
EPS NY rev (3m)-15.76%
Revenue NQ rev (1m)-56.06%
Revenue NQ rev (3m)-56.06%
Revenue NY rev (1m)-3.88%
Revenue NY rev (3m)-3.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.84
P/FCF N/A
P/OCF N/A
P/B 4.92
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.92
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.24
BVpS0.14
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -37.97%
ROE -138.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.52%
FCFM N/A
ROA(3y)-68.16%
ROA(5y)-56.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y0.93%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.49
Altman-Z -91.73
F-Score4
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y27.46%
EPS Next 2Y32.36%
EPS Next 3Y26.32%
EPS Next 5Y14.75%
Revenue 1Y (TTM)-13.43%
Revenue growth 3Y-2.41%
Revenue growth 5Y-2.72%
Sales Q2Q%-65.98%
Revenue Next Year3.67%
Revenue Next 2Y31.87%
Revenue Next 3Y64.75%
Revenue Next 5Y63.19%
EBIT growth 1Y26.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.97%
EBIT Next 3Y-7.64%
EBIT Next 5Y-10.32%
FCF growth 1Y31.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.25%
OCF growth 3YN/A
OCF growth 5YN/A

CURIS INC / CRIS Fundamental Analysis FAQ

What is the fundamental rating for CRIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRIS.


What is the valuation status of CURIS INC (CRIS) stock?

ChartMill assigns a valuation rating of 1 / 10 to CURIS INC (CRIS). This can be considered as Overvalued.


Can you provide the profitability details for CURIS INC?

CURIS INC (CRIS) has a profitability rating of 1 / 10.